ジェイファーマ株式会社 J-Pharma Co., Ltd.

  • News
  • About Us
  • Science
  • Pipeline
  • Business
  • Contact
Positive Response Received from U.S. FDA at CMC Type-C Meeting for  Novel Anticancer Candidate Drug Nanvuranlat – Important progress toward the start of Phase III Clinical Trial in the U.S.

News

    Archive

    • May 2025
    • April 2025
    • February 2025
    • January 2025
    • December 2024
    • October 2024
    • September 2024
    • July 2024
    • June 2024
    • May 2024
    • January 2024
    • December 2023
    • October 2023
    • June 2023
    • May 2023
    • April 2023
    • March 2023
    • January 2023
    • December 2022
    • May 2022
    • April 2022
    • January 2022
    • November 2021
    • July 2021
    • March 2021
    • February 2021
    • January 2021
    • July 2020
    • June 2020
    • December 2019
    • April 2019
    • December 2018
    • July 2018
    • May 2018
    • March 2018
    • January 2018
    • September 2017
    • May 2016
    • November 2015
    • April 2015
    • February 2015
    Contact

    Please contact us from here.

    Contact

    ジェイファーマ株式会社

    J-Pharma Co., Ltd.
    8th Floor, VORT Hamamatsucho II
    1-10-11 Hamamatsucho, Minato-ku, Tokyo 105-0013, Japan
    TEL 03-6432-4270 / FAX 03-6432-4271

    • TOP PAGE
    • News
    • About Us
    • Science
    • Pipeline
    • Business
    • Contact
    • Privacy

    COPYRIGHT © J PHARMA.CO.,LTD ALL RIGHTS RESERVED

    • EN
    • JP

    COPYRIGHT © J PHARMA.CO.,LTD ALL RIGHTS RESERVED

    • TOP PAGE
    • News
    • About Us
    • Science
    • Pipeline
    • Business
    • Contact
    • Privacy
    • EN
    • JP